Prikaz rezultata 1 – 5 od 5 za pretragu 'Seyed Reza Mousavi (13223324)', vrijeme upita: 0,01s Detaljiziraj rezultate
  1. 1
    The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.

    The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites. od Seyed Reza Mousavi (13223324)

    Izdano 2025
    Spremi u popis
    Spremljeno u:
  2. 2
    Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].

    Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58]. od Seyed Reza Mousavi (13223324)

    Izdano 2025
    Spremi u popis
    Spremljeno u:
  3. 3
    Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.

    Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites. od Seyed Reza Mousavi (13223324)

    Izdano 2025
    Spremi u popis
    Spremljeno u:
  4. 4
    Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.

    Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites. od Seyed Reza Mousavi (13223324)

    Izdano 2025
    Spremi u popis
    Spremljeno u:
  5. 5
    Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.

    Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites. od Seyed Reza Mousavi (13223324)

    Izdano 2025
    Spremi u popis
    Spremljeno u:

Alati za pretragu: